About this episode

This episode discusses a randomized controlled trial investigating obinutuzumab for systemic lupus erythematosus (SLE).

Good RCT this week, investigating the CD20 B cell inhibitor obinutuzumab for SLE. Sign up for my newsletter if you would like to have a read-along companion piece! Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2516150 Landing Page: https://ebrheum.com/ Substack: https://autoimmunedevreport.substack.com/

More episodes of The Evidence Based Rheumatology Podcast

• E134: Brepocitinib in Dermatomyositis (VALOR) · April 17, 2026 · 15 min
• E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE) · March 5, 2026 · 14 min
• E131: A Sham-Controlled Sham of a Trial: RESET-RA · January 21, 2026 · 15 min
• E130: Telitacicept for SLE · December 22, 2025 · 13 min
• E129: Long Term Routine Laboratory Monitoring in RA · December 4, 2025 · 15 min
• E128: Nerandomilast for Autoimmune ILD (FIBRONEER-ILD) · November 12, 2025 · 19 min

Explore listener stats, chart rankings, contacts and more on the The Evidence Based Rheumatology Podcast podcast page.